Pith. sign in

Paper Citation Record · LEDGER

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties

As of 8 August 2026, this Paper Citation Record lists 37 of 37 outbound references and 0 inbound Pith citation observations for arXiv:2506.03050.

A citation records a reference. It does not transfer a finding from one paper to another.

pith.paper-citation-record.v1
2506.03050 v1

Coverage vector

measured 37 of 37 reference resolution

Typed states for the displayed outbound observations.

Source: paper_references, paper_reference_links, observed 2026-08-07T11:21:20.870837Z

measured 37 of 37 standing notices

One-hop event checks from named stored sources.

Source: scholarly_work_events, retraction_status_cache, observed 2026-08-07T06:34:17.273281+00:00

measured 0 of 0 inbound itemization

Pith citing papers itemized under the disclosed page cap.

Source: paper_references, paper_reference_links

measured 0 of 1 external citation measurements

A source-named dated measurement, never combined with another source.

Source: cited_works

Reference resolution

37 of 37 outbound references displayed

  • verified exact0
  • verified fuzzy23
  • unresolved14
  • parse uncertain0
  • malformed identifier0
  • metadata mismatch0

External citation measurements

No source-named external measurement is stored.

Outbound references

Observation 3bc4a751-3e1c-489e-9251-023d0c860649 · outbound

This paper cites ://www.fda.gov/media/162416/download, available from: https://www.fda.gov/media/162416/download [Accessed 11th March 2024].

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties ://www.fda.gov/media/162416/download, available from: https://www.fda.gov/media/162416/download [Accessed 11th March 2024]

Reference 1

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.158941Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.760372Z digest=sha256:a814a6e5e09c80ffc944a87abdd53ad38604c336afb06d0ee1fb3f316a8bc968

Observation 3083a1ea-2fa8-45ed-8248-71e0ed6bf2ae · outbound

This paper cites Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289(19):2554--2559.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289(19):2554--2559

Reference 2

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.150381Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.764056Z digest=sha256:1219854c37e89ecb178ed1a0ccfdbe8a6df9a517c387ef07cc95bc7ff892fe90

Observation e44a426e-40a4-4a1e-b235-773071480b88 · outbound

This paper cites The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

Reference 3

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.141335Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.767596Z digest=sha256:96671f03a353ddd0282047f0a740d9f078c6b7e1b0ad180309d592e344cdf80a

Observation 983576df-1f5f-42ee-a29a-d9c0cbc65e5c · outbound

This paper cites Generalized pairwise comparisons of prioritized outcomes in the two-sample problem.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

Reference 4

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.133774Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.771355Z digest=sha256:f19a7820f42127ad40438a017a07c351ea09360fd2f80549c4438376a8fe0a37

Observation 5471d2ad-ed38-493f-a687-39098454b36e · outbound

This paper cites The win ratio: on interpretation and handling of ties.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties The win ratio: on interpretation and handling of ties

Reference 5

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.125650Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.774560Z digest=sha256:75e34997d2e8af7e38e9508cdd26c4e0935e336fde7c8b193b44fc548cb0fd32

Observation d92b2f11-25d4-4fd9-b064-a2027b83f8b8 · outbound

This paper cites Win odds: An adaptation of the win ratio to include ties.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Win odds: An adaptation of the win ratio to include ties

Reference 6

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.116338Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.778160Z digest=sha256:f272b92a3a7c971ae8463c1c19f212dee5a0e2035a28605e079b692b88e49b28

Observation c5d168da-d437-4a1b-8926-a39d28a053ca · outbound

This paper cites An alternative approach to confidence interval estimation for the win ratio statistic.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties An alternative approach to confidence interval estimation for the win ratio statistic

Reference 7

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.109123Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.782049Z digest=sha256:1fc0d0d31a5903f67dc226259e560e94634871edfabeb5f72dd06f458a051d5e

Observation 084d49e8-390b-43c9-9499-c4f48eeb49c3 · outbound

This paper cites Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Large sample inference for a win ratio analysis of a composite outcome based on prioritized components

Reference 8

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.101073Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.785440Z digest=sha256:96ad2db8e6f87d0c570ebbafe35cc01f2385f5c2a1772782d3640a56add5d1bc

Observation c0885589-9ac2-42ac-ae79-878fcd3f5ecc · outbound

This paper cites On the win-ratio statistic in clinical trials with multiple types of event.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties On the win-ratio statistic in clinical trials with multiple types of event

Reference 9

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.093818Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.789634Z digest=sha256:a70e643f93e583baa1420d9d10f443f4852716735c173927b3b16bec6fe0290d

Observation dd35fa49-2901-491e-ae05-6a803eb42e99 · outbound

This paper cites Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial

Reference 10

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.086892Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.792100Z digest=sha256:e54ec6906f792b5c4495bfb6cf696f7199c19143242a4487833894dc8b169eea

Observation ec4d0641-658a-4a9e-b96a-2c2ef5b5419b · outbound

This paper cites an unresolved cited work.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Unresolved cited work

Reference 11

Resolution
unresolved
raw_fallback, observed 2026-08-07T11:21:21.078899Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.794901Z digest=sha256:f92b66938115c7522171a493dda5e07f11f3d0f846091bf12ca4b5190f35d75c

Observation 97a53203-2c71-4542-b142-b2f2d63fee04 · outbound

This paper cites On recurrent-event win ratio.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties On recurrent-event win ratio

Reference 12

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.070950Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.797672Z digest=sha256:9174aa829c2ca4eeb24fe20250723eb52fbb4f1c6b4647749aacf0773d8d9452

Observation cf57e4b5-a40a-409f-9dcc-ac5c77a49630 · outbound

This paper cites The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards

Reference 13

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.063073Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.800174Z digest=sha256:fcb9a99af37d115c89a62b951a5fecc422ee11da3c1b53411e13d48ea7caa71d

Observation 4dc118ed-2869-4d09-b376-df2e067e9378 · outbound

This paper cites The inverse-probability-of-censoring weighting ( IPCW ) adjusted win ratio statistic: An unbiased estimator in the presence of independent censoring.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties The inverse-probability-of-censoring weighting ( IPCW ) adjusted win ratio statistic: An unbiased estimator in the presence of independent censoring

Reference 14

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.054427Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.802592Z digest=sha256:fc7ee167d03d7165f0c2a7a8fef391ff9d2ad661aae7a9fdc94f4e4d31711cab

Observation 76722439-154c-4bfb-b91f-c1bfdfed1d96 · outbound

This paper cites Adjusting win statistics for dependent censoring.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Adjusting win statistics for dependent censoring

Reference 15

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.045764Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.805216Z digest=sha256:b6d294a3c8260edad3800adc70b083184032143db0aeec8e6b5334d6278ca5df

Observation b318705a-edba-42e9-a60d-0522349af218 · outbound

This paper cites Win-loss parameters for right-censored event data, with application to recurrent events.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Win-loss parameters for right-censored event data, with application to recurrent events

Reference 16

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.036729Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.807873Z digest=sha256:84adf3cf0596d9758b62b1151f76106ea2e1439716d0784daa603d2d1136a8f5

Observation eb16dec3-b54a-4779-b1e4-d9be99d6eb0a · outbound

This paper cites Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis

Reference 17

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.026459Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.810826Z digest=sha256:60d5b3429dc4c036a3669061a6e81db45c58d2e45c95c23e4bd656cbb27aca27

Observation 562fd213-ee08-4d1b-b705-b7d59db14d16 · outbound

This paper cites On the empirical choice of the time window for restricted mean survival time.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties On the empirical choice of the time window for restricted mean survival time

Reference 18

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.017225Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.814033Z digest=sha256:ac72f8be4a8c2074ed12d789229aae7895699708b99ee49f2ae8fb7a8696b8f4

Observation e9f311dc-b9dc-4d69-8319-380a64f1c4c6 · outbound

This paper cites Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments

Reference 19

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:21.008226Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.816848Z digest=sha256:560c25dcee120fd8e72801996c1cd82fdd9508e3f67f2fc16e82a33dcc14d178

Observation 03d5ee6a-af30-4309-bb02-fb3562151482 · outbound

This paper cites Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma

Reference 20

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:20.999518Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.819350Z digest=sha256:20c6a2463a64953fbb5eb1737c28530e2ab6c2c9785ad71648153b322d439888

Observation e001bcd1-51e5-4a47-b936-3d5e026fc4ab · outbound

This paper cites Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Reference 21

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:20.989142Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.822665Z digest=sha256:9129aa6b33d732a0816975a77a4b8ee532feab7a0d31e5e0cfd8b2b9272deb5f

Observation 8933dbfa-11e3-497f-bf42-124702b7b460 · outbound

This paper cites When you look matters: the effect of assessment schedule on progression-free survival.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties When you look matters: the effect of assessment schedule on progression-free survival

Reference 22

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:20.978994Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.825235Z digest=sha256:3429287aa16eb1d1f86fae857a284b9b6ca7feb2150a9ab9e0d2c6758c0c768f

Observation 5aeb6b79-042e-4606-9cb9-bf9301f7648a · outbound

This paper cites American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes

Reference 23

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:20.970368Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.827684Z digest=sha256:122ca60a3e43823571408a054cea8ede806ce3c68f6d1129ec2ccb249d362f9c

Observation 97114303-d106-4f09-a087-dc8ee7b171cb · outbound

This paper cites Treatment selections using risk--benefit profiles based on data from comparative randomized clinical trials with multiple endpoints.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Treatment selections using risk--benefit profiles based on data from comparative randomized clinical trials with multiple endpoints

Reference 24

Resolution
verified fuzzy
raw_fallback, observed 2026-08-07T11:21:20.960672Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.830671Z digest=sha256:6bf2bc658c40a6e03a2bc1e909b1c46ac2ba5683dc8264f0b12febb0482d0761

Observation 6f9a3c60-ae35-42d5-ae3f-7ef48b6b6175 · outbound

This paper cites an unresolved cited work.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Unresolved cited work

Reference 25

Resolution
unresolved
raw_fallback, observed 2026-08-07T11:21:20.949729Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-07T06:34:17.273281+00:00.

source=arxiv_source observed=2026-08-07T11:21:20.833509Z digest=sha256:35b462013783073e98749e19dbf6473200dff94b0f142f6a99bc57fe00be6cf9

Observation 4d0c1927-eacf-4b46-a408-ccc6bcf57078 · outbound

This paper cites write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties write newline

Reference 26

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.836226Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.836226Z digest=sha256:c319f5a134371c81023593780b78b4c080518f174b305d409e1a17b7ddf41d3b

Observation df1ab362-b400-47a7-aa80-c5783cfeecd6 · outbound

This paper cites , " * write output.state after.block = add.period write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties , " * write output.state after.block = add.period write newline

Reference 27

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.839458Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.839458Z digest=sha256:d3788fc9cd61a52ab9d117579fa9af9b87194698bdf399acd4ca893624ef884a

Observation 7e0042b1-d871-4041-8249-68d0bcb6ee63 · outbound

This paper cites write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties write newline

Reference 28

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.842807Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.842807Z digest=sha256:26b2c180e8b3ea08dcf4f9e7454d22ad061783c7f6837f89633897ef9980e713

Observation c931f794-8abf-46e6-8e37-93cb34e16883 · outbound

This paper cites write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties write newline

Reference 29

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.845780Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.845780Z digest=sha256:8f8a85f2c415affbb7a29d877cc6cc1ef3d3f5f0ff7ed9c065822955363de00e

Observation d05b341c-4a74-4f9b-988f-07f858f8a15d · outbound

This paper cites write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties write newline

Reference 30

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.848655Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.848655Z digest=sha256:0c7590f303a213042e2b53b19f421c08e6717952c74b8220dbda9ae6e2c149ff

Observation 8e62d2bc-194b-42f9-9b04-fe96b677f207 · outbound

This paper cites write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties write newline

Reference 31

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.851928Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.851928Z digest=sha256:40a4caaa5b70a5c3aefb086d0a32fb9165df9f75ab59e62e428be633ec01f31f

Observation dc9d6f14-17d6-44db-aeec-743a159c078b · outbound

This paper cites , " * write output.state after.block = add.period write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties , " * write output.state after.block = add.period write newline

Reference 32

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.855947Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.855947Z digest=sha256:a721b73e4873e2e61b1e21465944e246d205f143a435a198d74d4536cf6b435c

Observation 02fa08af-0fdb-4352-b321-716ff9688b2d · outbound

This paper cites write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties write newline

Reference 33

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.859373Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.859373Z digest=sha256:a35b87acc4edfe96c74d1c1eca16a664e63471aa42ca7d84bcb815eaad4dfa03

Observation 6466451d-66f5-4dfa-ab7c-3cc6e3caf4fb · outbound

This paper cites write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties write newline

Reference 34

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.862106Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.862106Z digest=sha256:5ad5213f79ec67d77e5a3e07f6c1834c065aee4beb34a1f664d6eb67fa914f50

Observation de63131d-f549-4f22-b9e6-3a27246d20cb · outbound

This paper cites write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties write newline

Reference 35

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.864966Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.864966Z digest=sha256:302000bfdda9e73984c61b8c24de9bd82572e91e0b7b9eeeac33021efaa46c5f

Observation 88573247-5cee-4e99-8c39-833e4302d03c · outbound

This paper cites Available from:.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties Available from:

Reference 36

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.868059Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.868059Z digest=sha256:5c97b8511f3e43875014a8f6f22003991e9fcbcd2a3e59ca3bfe97ec3cf51eb3

Observation e4280ba1-09a2-4519-b71e-659f3556e57c · outbound

This paper cites write newline.

An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties write newline

Reference 37

Resolution
unresolved
no resolver link, observed 2026-08-07T11:21:20.870837Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=arxiv_source observed=2026-08-07T11:21:20.870837Z digest=sha256:7c12924e5939d87e8aefc5b3edbc7fba0f6dc5ec05405d97e4e73efd5e3f0111

Pith citing papers

No inbound Pith citation observations are available.